Please assess the completion status of the following clinical trial:

Trial Title: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 50 years of age or older diagnosed in the study eye with subfoveal choroidal neovascularization (CNV) or juxtafoveal CNV secondary to AMD~* Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 65 to 10 in the study eye~* Willing and able to comply with clinic visits and study-related procedures~* Provide signed inform consent~Exclusion Criteria:~* Macular edema or CMV secondary to any causes other than AMD in the study eye~* Previously-treated patients who are not responders to anti-VEGF~* Any condition that may preclude improvement in visual acuity in the study eye~* Previous vitreoretinal surgery, filtration surgery, and cataract surgery within 3 months in the study eye~Note: Other inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): AXT107 0.1 mg/eye
- Mid Dose (Type: EXPERIMENTAL): AXT107 0.25 mg/eye
- High Dose (Type: EXPERIMENTAL): AXT107 0.5 mg/eye

Based on this trial design, predict the completion outcome and termination type (if applicable).